Home › Topics › Rubella

Rubella

GMJ News knowledge hub · last reviewed August 2026 · Georgian Medical Journal

SummaryStatisticsGlossaryGMJ newsFAQDocumentsOrganizationsResearch

Rubella — caused by rubella virus (Matonaviridae), transmitted by respiratory droplets — causes a characteristically mild illness in children (low-grade fever, suboccipital and posterior auricular lymphadenopathy, fine maculopapular rash lasting 3 days), but is devastating in pregnancy: infection in the first trimester causes congenital rubella syndrome (CRS) in over 80% of exposed fetuses — deafness, cataracts, heart defects and brain damage — making rubella control a reproductive health imperative rather than a routine childhood vaccine programme (WHO). Despite highly effective MMR vaccine, WHO’s 2030 rubella elimination target is threatened by large outbreaks in under-vaccinated communities — including significant outbreaks in Romania, Poland and Ukraine in recent years — demonstrating that rubella elimination requires sustained ≥97% two-dose MMR coverage.

Key messages

Mild in children — devastating in pregnancy (CRS 80% in first trimester)
Rubella infection in adults and older children is generally mild (low-grade fever, rash, lymphadenopathy). But rubella in the first trimester of pregnancy causes congenital rubella syndrome (CRS) in over 80% of fetuses — deafness, cataracts, heart defects, brain damage. One rubella case in a pregnant unvaccinated woman can cause lifelong disability in the child (WHO).
Suboccipital lymphadenopathy — the clinical clue
The pathognomonic lymphadenopathy of rubella: suboccipital (at the base of the skull), posterior auricular (behind the ears) and posterior cervical nodes — tender, enlarged, appearing 5-10 days before the rash. This lymphadenopathy pattern distinguishes rubella from measles and other exanthemata.
MMR vaccination — the only prevention
Two doses of MMR vaccine achieve >97% rubella protection — one of the most effective vaccines available. Achieving ≥97% two-dose MMR coverage in all populations (especially girls and women of reproductive age) is essential for CRS elimination.
ECDC outbreaks in under-vaccinated communities — ongoing
Large rubella outbreaks in Romania, Poland and Ukraine in recent years (2019-2023) — primarily in unvaccinated communities — demonstrate that WHO's 2030 rubella elimination target remains at risk without sustained high MMR coverage.
Post-infection arthritis — common in adult women
Arthralgia and arthritis are common in adult women infected with rubella (up to 70%) — affecting fingers, wrists and knees. Self-limiting in most, but can persist for weeks to months. Rarely, a chronic arthropathy resembling rheumatoid arthritis can develop.
Georgia context — rubella vaccination history
Georgia introduced MMR into its national immunisation programme in the 2000s as part of post-Soviet vaccination system reform. PHIG monitors vaccination coverage and rubella serosurveillance, with particular attention to women of reproductive age.

Key statistics

>80%
CRS risk if rubella acquired in first trimester of pregnancy
WHO
~100K
CRS births estimated globally each year (pre-elimination settings)
WHO
>97%
rubella protection from 2-dose MMR vaccine
WHO
2030
WHO target: rubella and CRS elimination in all WHO regions
WHO
70%
of adult women with rubella develop arthralgia/arthritis
WHO
ECDC
ongoing outbreaks in under-vaccinated communities; Romania, Poland, Ukraine
ECDC 2019-2023

Congenital rubella syndrome (CRS) risk by gestational age at maternal infection

Source: WHO. CRS risk is highest in the first trimester; falls dramatically after 20 weeks.

Glossary of key terms

Rubella virus
WHOA positive-sense, single-stranded RNA virus — family Matonaviridae (recently reclassified from Togaviridae), genus Rubivirus. Single serotype — one of the few human RNA viruses with only one serotype. Exclusively human; no animal reservoir. Transmitted by respiratory droplets; highly contagious (R0 approximately 5-7, similar to mumps; less than measles).
Forchheimer spots
WHO/ClinicalPetechial lesions on the soft palate — appearing just before or with the rash in approximately 20% of rubella cases. Not pathognomonic (also seen in mononucleosis) but clinically helpful. Named after Frederick Forchheimer (1848-1913), an American physician.
Congenital rubella syndrome (CRS)
WHOCovered in detail in the congenital-rubella-syndrome hub. Major features: Deafness (sensorineural — most common single defect, approximately 60-75%); cataracts (approximately 25-50%); congenital heart disease (patent ductus arteriosus, pulmonary artery stenosis — approximately 25-50%); microcephaly; intellectual disability; growth restriction. Gregg's triad (classic description by Norman Gregg 1941): cataracts + cardiac defect + deafness.
Rubella serosurveillance
ECDC/WHORegular measurement of anti-rubella IgG seroprevalence (proportion immune) in women of reproductive age — to identify gaps in herd immunity that put pregnancies at risk. WHO requires surveillance in all WHO Member States. Priority: ensure >95% seroimmunity in women aged 15-44 years.
Differentiation from measles and roseola
WHO/ClinicalRubella (3rd disease): fine pink maculopapular rash descending from face → trunk → extremities over 3 days; suboccipital and posterior auricular lymphadenopathy (pathognomonic); low-grade fever; no Koplik spots; no significant cough/coryza. Measles: high fever >40°C; Koplik spots (buccal mucosa — pathognomonic); intense coryza, cough, conjunctivitis BEFORE rash; severe systemic illness. Roseola (HHV-6): high fever for 3-5 days → THEN rash as fever resolves (rose-coloured spots on trunk); predominantly infants. Parvovirus B19 (5th disease): slapped-cheek red facial rash → reticular rash on limbs; no fever.
MMR in pregnancy — contraindicated
WHO/CDCMMR vaccine (a live attenuated vaccine) is contraindicated in pregnancy — theoretical risk of fetal infection from the vaccine virus (no confirmed cases of vaccine-induced CRS have ever been documented, but the theoretical risk justifies avoidance). Protocol: test rubella immunity before pregnancy; vaccinate non-immune women at least 4 weeks before conception; vaccinate immediately post-partum if seronegative. Accidental MMR vaccination in early pregnancy is NOT an indication for termination.

Latest GMJ coverage

UK Guidance on Inadvertent Vaccination in Pregnancy: What Healthcare Providers Need to Know
14/07/2026
Florida’s Push to End School Vaccine Mandates Stalls: What the Setback Reveals
11/08/2026
PAHO Urges Enhanced Measles Surveillance Ahead of 2026 FIFA World Cup
05/06/2026
England Reports 2,468 Laboratory-Confirmed Measles Cases as Epidemic Intensifies
01/06/2026
Colorado Forms Vaccine Coalition as Federal Support Weakens
27/05/2026

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Congenital rubella syndromeMeasles (MMR triplet)Mumps (MMR triplet)MMR vaccinationAntenatal rubella screeningCongenital anomalies

About this hub. Produced by the GMJ News Editorial Team as a public-good service. Every statistic is linked to its primary source. Documents are preserved in the GMJ Repository with full attribution. Georgian Medical Journal · Contact the editorial team
GMJ BriefsView all →
●Quality Alert: Filler Content in Mushroom Supplements Undermines Clinical Claims2 hours ago●Announcement: Five Foods Cardiologists Recommend for Men’s Heart Health: Evidence from Clinical Practice2 hours ago●Three Essential Lessons from HPV Vaccination Success: What Healthcare Leaders Should Know2 hours ago●What Healthcare Leaders Need to Know About 340B Enforcement and Claims Data Compliance32 minutes ago●Extended Exercise Demands High Sodium: Why Water Alone Is Insufficient10 minutes ago●Announcement: Wide disparities in congenital heart disease detection across Argentina revealed by national registry data10 minutes ago●Three Actionable Insights from Ontario's Benzodiazepine Study for Clinical Practice28 minutes ago●Three Essential Principles for Implementing Perioperative Immunotherapy in Bladder Cancer1 hour ago●Seven Biological Pathways: How Resistance Training Protects the Aging Brain2 hours ago●Announcement: Early sexual initiation in Zambia: New data reveals age 17 median, literacy as protective factor2 hours ago